You are viewing a preview of...

Bioactive Compounds for Use in Inhibiting SARS-CoV-2 Viral Replication

This invention is the discovery of inhibitors targeting the SARS-CoV-2 main protease, with potential use as therapeutics against COVID-19

Background

Viral outbreaks are not new; we have faced SARS, MERS, Nipah, Zika, and several other viral outbreaks in recent history. In November or December of 2019, a novel coronavirus, SARS-CoV-2 (COVID-19), started to circulate through humans. The World Health Organization has declared this outbreak a pandemic due to its high transmission rates.

COVID-19 is a beta coronavirus, similar to the human coronaviruses SARS and MERS. With this novel outbreak, there are now seven different strains of human coronaviruses. Coronaviruses are proving, over time, to be a severe threat to humans. Novel treatments that work against conserved areas will be beneficial in the short and long-term as we try to overcome the current and future pandemics.

Log in or create a free account to continue reading